Impaired astrocyte-to-neuron cholesterol trafficking drives synaptic dysfunction in Rett syndrome

Technical Summary: Impaired astrocyte-to-neuron cholesterol trafficking drives synaptic dysfunction in Rett syndrome

Problem Statement
Rett syndrome (RTT), a severe neurodevelopmental disorder caused by loss-of-function mutations in MECP2, is characterized by profound synaptic dysfunction and impaired neuronal maturation. While neuronal defects are well-documented, recent evidence highlights the critical role of non-cell-autonomous mechanisms, specifically astrocyte dysfunction, in driving RTT pathogenesis. Although alterations in brain cholesterol metabolism have been reported in RTT models and patients, the specific cellular mechanisms linking Mecp2 deficiency to defective astrocyte-neuron communication remain poorly understood. Crucially, it is unknown whether impaired cholesterol trafficking from astrocytes to neurons contributes to synaptic failure or if restoring cholesterol availability could serve as a therapeutic strategy.

Methodology
The study employed a multi-faceted approach combining in vitro and in vivo models to characterize cholesterol homeostasis in Mecp2 deficiency:

• Animal Models: The researchers utilized Mecp2 knock-out (KO) and heterozygous (HET) mice, including the Mecp2Y120D knock-in model. Studies were conducted on both primary cultures derived from post-natal pups (P1-P3) and acutely isolated astrocytes from adult mice (P7 and P40).
• Cellular Models: Primary cortical astrocytes and neurons were cultured. Astrocyte-conditioned medium (ACM) was prepared to assess soluble factors affecting neuronal health.
• Molecular Analysis:
  • Gene Expression: qRT-PCR was performed on astrocytes and cerebral tissues to quantify transcripts of cholesterol biosynthesis (e.g., Nsdhl, Hmgcr, Sqle) and transport genes (e.g., Abca1, Abcg1, Lcat).
  • Protein Analysis: Western blotting assessed protein levels of Srebp2, Nsdhl, Abca1, Lcat, and ApoE. Non-denaturing gel electrophoresis was used to evaluate the lipidation state of ApoE.
  • Localization: Immunofluorescence (IF) was used to determine the subcellular localization of Srebp2 and to quantify synaptic puncta (Synapsin1/2, Shank2) and axon initial segment (AIS) length (AnkyrinG).
  • Cholesterol Quantification: Intracellular and secreted cholesterol levels were measured using Gas Chromatography-Mass Spectrometry (GC-MS), the Amplex Red enzymatic assay, and High Performance Thin Layer Chromatography (HPTLC). Filipin staining was used to visualize free intracellular cholesterol.
• Functional Rescue: Primary neurons were treated with ACM from KO astrocytes, with or without exogenous cholesterol supplementation (complexed with methyl-β-cyclodextrin). Synaptic density and AIS morphology were analyzed to assess rescue effects.

Key Results

1. Transcriptional and Regulatory Defects: Mecp2 KO astrocytes exhibited a significant reduction in the nuclear localization of Srebp2, the master transcriptional regulator of cholesterol homeostasis, despite unchanged total Srebp2 protein and mRNA levels. This led to a broad downregulation of genes involved in cholesterol biosynthesis (Nsdhl, Hmgcr, Mvk, Sqle) and transport (Abca1, Abcg1, Lcat). These transcriptional changes were validated in both cultured astrocytes and acutely isolated astrocytes from KO mice.
2. Intracellular Accumulation vs. Secretion Defects: Contrary to the downregulation of biosynthetic genes, Mecp2 KO astrocytes showed an accumulation of intracellular free cholesterol and its precursor desmosterol. This accumulation likely triggers a negative feedback loop inhibiting Srebp2 nuclear translocation. While total cholesterol secretion into the ACM remained unchanged, the functional delivery of cholesterol was impaired.
3. Defective ApoE Lipidation: Although ApoE expression levels were preserved in KO astrocytes, the lipidation of ApoE was significantly reduced. This defect correlated with the downregulation of Abca1, the transporter responsible for loading cholesterol onto ApoE. Consequently, the ACM from KO astrocytes contained fewer lipidated ApoE complexes, which are essential for cholesterol delivery to neurons.
4. In Vivo Validation: These molecular alterations were recapitulated in vivo. Symptomatic Mecp2 KO mice showed increased cortical cholesterol levels, reduced expression of cholesterol-related genes (Nsdhl, Hmgcr, Sqle, Cyp51), and reduced Abca1 protein levels in the cortex. Similar defects were observed in the Mecp2Y120D model.
5. Functional Rescue: Treatment of wild-type neurons with KO-ACM resulted in reduced pre- and post-synaptic density. Supplementation of KO-ACM with exogenous cholesterol fully rescued these synaptic defects. Furthermore, direct cholesterol treatment of Mecp2 HET neurons restored synaptic puncta density and corrected the distribution of AIS lengths, reducing the proportion of neurons with abnormally short AIS.

Significance and Claims
The paper identifies defective astrocyte-to-neuron cholesterol trafficking as a key mechanism driving synaptic dysfunction in Rett syndrome. The authors argue that the primary defect is not a lack of total cholesterol in the brain, but rather a failure in its functional availability and trafficking to neurons due to impaired ApoE lipidation.

The study claims that:

• Impaired cholesterol homeostasis in RTT extends beyond in vitro models, being present in acutely isolated astrocytes and the cerebral cortex of symptomatic mice.
• The accumulation of intracellular cholesterol in astrocytes paradoxically suppresses the transcriptional machinery required for cholesterol export, creating a bottleneck in delivery to neurons.
• Strategies aimed at restoring the functional availability of cholesterol to neurons, rather than simply lowering total brain cholesterol levels (e.g., via statins), represent a promising therapeutic avenue.
• Exogenous cholesterol supplementation can bypass the astrocytic trafficking defect, rescuing synaptic morphology and neuronal excitability markers (AIS length) in RTT models.

The authors conclude that targeting cholesterol metabolism to improve its trafficking from astrocytes to neurons offers a novel therapeutic strategy for RTT, supported by the observation that bypassing the astrocytic defect rescues neuronal phenotypes.